



Original article

Cumulative incidence of solid and hematological *De novo* malignancy after liver transplantation in a multicentre cohort

Cristina Lucidi^{a,1}, Marco Biolato^{b,c,1}, Quirino Lai^d, Barbara Lattanzi^a, Ilaria Lenci^e, Martina Milana^e, Raffaella Lionetti^f, Antonio Liguori^c, Mario Angelico^e, Giuseppe Tisone^g, Alfonso Wolfango Avolio^{b,c}, Salvatore Agnes^{b,c}, Massimo Rossi^d, Antonio Grieco^{b,c}, Manuela Merli^{a,*}

^a Gastroenterology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

^b Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

^c Catholic University of the Sacred Heart, Rome, Italy

^d Hepato-biliopancreatic and Liver Transplant Unit, Department of Surgery, Sapienza University of Rome, Rome, Italy

^e Hepatology Unit, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, Rome, Italy

^f Infectious and Liver Diseases, Lazzaro Spallanzani National Infectious Disease Institute, Rome, Italy

^g Surgery Unit, Department of Experimental Medicine and Surgery, Tor Vergata University Hospital, Rome, Italy

ARTICLE INFO

Article history:

Received 29 September 2020

Accepted 16 December 2020

Available online 20 January 2021

Keywords:

Liver transplant

Cancer

Neoplasms

Complication

ABSTRACT

Background: Recent innovations in the field of liver transplantation have led to a wealth of new treatment regimes, with potential impact on the onset of *de novo* malignancies (DNM). The aim of this multicenter cohort study was to provide contemporary figures for the cumulative incidences of solid and hematological DNM after liver transplantation.

Methods: We designed a retrospective cohort study including patients undergoing LT between 2000 and 2015 in three Italian transplant centers. Cumulative incidence was calculated by Kaplan–Meyer analysis.

Results: The study included 789 LT patients with a median follow-up of 81 months (IQR: 38–124). The cumulative incidence of non-cutaneous DNM was 6.2% at 5-years, 11.6% at 10-years and 16.3% at 15-years. Post-Transplant Lymphoproliferative Disorders (PTLD) were demonstrated to have a cumulative incidence of 1.0% at 5-years, 1.6% at 10-years and 2.2% at 15-years. Solid Organ Tumors (SOT) demonstrated higher cumulative incidences – 5.3% at 5-years, 10.3% at 10-years and 14.4% at 15-years. The most frequently observed classifications of SOT were lung (rate 1.0% at 5-years, 2.5% at 10-years) and head & neck tumors (rate 1.3% at 5-years, 1.9% at 10-years).

Conclusions: Lung tumors and head & neck tumors are the most frequently observed SOT after LT.

© 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Long term graft survival after liver transplantation (LT) currently exceeds 55% at 10 years [1] but 10-year survival is 21% lower than expected for the general population [2]. Malignancies (both recur-

rent and *de novo*) are the most common cause of death in patients surviving at least one year after LT [2,3] and the cumulative risk increases with age and the temporal distance from the transplant [4]. In an analysis of the Scientific Registry of Transplant Recipients from 1987 to 2009, LT patients were found to carry an 11-fold higher risk of developing non-skin *de novo* malignancy (DNM) than the general population [5].

The most important precipitant of DNM in transplanted patients is chronic immunosuppression [6]. Immunosuppressive therapy increases the risk of neoplasia through several mechanisms including reduced immunological surveillance, increased susceptibility to infections with possible oncogenic effects, induction of insulin resistance and a speculative direct mutagenic action [7,8]. Furthermore, the effects of conventional risk factors for neoplasia (i.e., alcohol, smoking, pre-cancerous lesions) can be exacerbated by decreased immuno-competence [9].

Abbreviations: ALF, acute liver failure; CI, confidence intervals; CMV, cytomegalovirus; DNM, *de novo* malignancy; EBV, Epstein–Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; LT, liver transplantation; MMF, mofetil mycophenolate; PTLT, post-transplant lymphoproliferative disease; SE, standard error.

* Corresponding author at: Gastroenterology, Department of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, Rome, Italy.

E-mail address: manuela.merli@uniroma1.it (M. Merli).

¹ These authors contributed equally to this work.

<https://doi.org/10.1016/j.aohep.2021.100309>

1665-2681/© 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Recent innovations in the field of LT have led to changes in the management of transplant patients, with a potential impact on the onset of DNM after LT. Calcineurin inhibitors (cyclosporin and tacrolimus) have been consistently associated, in a dose-dependent fashion, with an increased risk of both Hepatocellular Carcinoma (HCC) recurrence and DNM incidence [10], hence minimizing levels of immunosuppression is widely practiced. The combination of antiproliferative and immunosuppressant activity of mTOR inhibitors (everolimus and sirolimus) make them attractive in post-LT setting. Despite the promising biological rationale, retrospective studies and an open-label clinical trial did not convincingly demonstrate lower rates of HCC recurrence in patients receiving mTOR inhibitors [10,11]. Despite early evidence of lower incidence of DNM in patients treated with mTOR inhibitors these benefits remain largely unsubstantiated [12].

Regarding indications, in recent years LT performed for non-alcoholic steatohepatitis (NASH) increased significantly whereas transplant for Hepatitis C virus (HCV) significantly reduced as a consequence of the introduction of the new direct acting antivirals [13]. Since NASH may be a risk factor for extra-hepatic cancers, such colorectal cancer [14], this may have an impact on DNM incidence in future.

Given that the clinical population undergoing LT and the treatment of these patients has changed significantly in recent years, it stands to reason that antiquated data may not be generalizable to modern practice. The aim of this multicenter cohort study is to provide contemporary figures for the cumulative incidences of solid and hematological DNM after LT.

2. Patients and methods

We designed a retrospective cohort study including all adult patients undergoing LT between 2000 and 2015 in three transplant centers (Umberto I University Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Fondazione Policlinico Tor Vergata) in Rome, Italy. All patients were followed periodically, and information were collected accurately for any DNM.

Exclusion criteria were:

- a) re-transplantation;
- b) multi-organ transplantation;
- c) pediatric (<18 years) transplantation;
- d) patients with a post-transplant follow-up shorter than six months, the latter because cancer is a time-dependent event and these patients were not at risk of developing DNM.

For each transplanted patient the following variables were collected: date of transplantation, age at transplant, gender, indication for LT, any alcohol relapse/slip after LT, smoking pattern, immunosuppressive therapy, post-LT Cytomegalovirus (CMV) infection, post-LT Epstein Barr Virus (EBV) infection, pre-LT history of cancer, patient survival, and causes of death. Post-LT EBV and CMV infection were diagnosed by CMV DNA and EBV DNA quantitative analysis. Protocols for EBV viremia surveillance were introduced in 2012–2013 and foresee EBV DNA viremia every 2–4 weeks in the first 3 months, monthly until 6 months post-transplantation and then every 3 months for the rest of the first year in patients with donor seropositive/recipient seronegative status.

For cases of DNM, data collected included the timing, presence of a surveillance program, characteristics of clinical presentation, staging at diagnosis, treatment and outcomes.

2.1. Immunosuppression

The immunosuppressive protocols depended on the year of transplantation and choices of the center. Over the years, 12 dif-

ferent primary immunosuppression regimens had been combined, as shown in Table 1. The most common regimens included a calcineurin inhibitor (cyclosporin or tacrolimus) and mycophenolate mofetil. About 7% of patients received everolimus-based immunosuppression. Additionally, a minority of the LT recipients, especially those with concomitant severe renal failure, received induction therapy with an anti-thymocyte globulin or monoclonal antibodies directed against interleukin 2 receptors. Based on clinical judgment, patients with an acute cellular rejection were treated with 3 intravenous boluses of methylprednisolone (500 mg). Steroid-resistant rejection was treated with anti-thymocyte globulin.

2.2. Screening protocols

Before transplant all candidates (except those with acute liver failure) underwent thorough tumor screening including chest radiography, abdominal computed tomography, gastroscopy, colonoscopy, mammography, Papanicolaou smear, transvaginal pelvic ultrasound, and prostate-specific antigen assessment.

Post-LT cancer surveillance strategies (Supplementary Table 1) at each of the three centers were similar. Strategies included annual mammography starting at the age of 40 years, annual Papanicolaou smear, annual prostate-specific antigen starting at the age of 50 years and colonoscopy every 5 years (or annually in patients with primary sclerosing cholangitis and inflammatory bowel disease).

A screening protocol for skin cancers (annual dermatological exam) was adopted, identifying a small number of early melanomas (all Breslow depth <1 mm) and other skin cancers. These were not included in our analysis as these tumors have a very limited impact on mortality in LT patients [15]. In our cohort we had no cases of metastatic skin cancer of any type.

2.3. Statistical analysis

Continuous variables were reported as medians and interquartile ranges (IQR). Categorical variables were reported as numbers and percentages. We used the maximum likelihood estimation method for managing missing data: in each variable, less than 10% of the data was initially missing. Kruskal–Wallis and chi-squared Pearson tests were used for comparisons of continuous and categorical variables, respectively.

Post-LT HCC recurrence was not considered as an event in the present study. Consequently, patients that developed HCC were censored at the last follow-up date. Survival probabilities were estimated using the Kaplan–Meier method.

Cox regression models were constructed to identify risk factors for post-LT DNM and post-DNM-related death. All covariates showing a *p*-value <0.2 in univariate analysis were used for the construction of the multivariable Cox regression analysis. Hazard ratios (HR) and 95% confidence intervals (95%CI) were reported.

Cumulative incidence was calculated at 5, 10 and 15 years from LT by Kaplan–Meyer analysis.

Variables with a *p*-value <0.05 were considered statistically significant. All statistical analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Study population

Between 2000 and 2015, 968 patients were transplanted at the three transplant centers. 22 patients were excluded because of re-transplantation, 7 patients because of multi-organ transplantation, 11 patients because of pediatric transplantation and 139 patients because they had a post-transplant follow-up shorter than six months. The study population included 789 patients.

Table 1
Patients' characteristics in the three Centers.

Variables	Overall (n = 789) Median (IQR) or n (%)	Centre A (n = 302)	Centre B (n = 254)	Centre C (n = 233)	P
Age at transplant (years)	55 (47–60)	56 (48–60)	51 (44–58)	56 (49–61)	0.001
Male gender	600 (76.0)	234 (77.5)	188 (74.0)	178 (76.4)	NS
Indications for LT (percentage)*					
HCV-related cirrhosis	310 (39.1)	48 (15.9)	40 (15.7)	47 (20.2)	NS
HBV-related cirrhosis	135 (17.1)	93 (30.8)	99 (39.0)	55 (23.6)	0.001
Alcohol-related cirrhosis	247 (31.1)	2 (0.7)	5 (2.0)	17 (7.3)	<0.001
Autoimmune disease	24 (3.0)	10 (3.3)	7 (2.8)	1 (0.4)	NS
Coeliac diseases (PBC and PCS)	18 (2.3)	9 (3.0)	9 (3.5)	11 (4.7)	NS
Acute Liver Failure	29 (3.7)	17 (5.6)	0 (0)	9 (3.9)	NS
Cryptogenic cirrhosis	26 (3.2)	120 (40.0)	96 (38.0)	77 (33.0)	0.04
Hepatocellular Carcinoma co-indication	293 (35.8)				
History of alcohol use disorder	278 (35.2)	89 (29.5)	100 (39.4)	89 (38.2)	<0.001
Smoking (current or previous)	176 (22.3)	62 (20.6)	7 (2.8)	107 (45.9)	<0.001
Current	73 (9.2)	27 (8.9)	4 (1.6)	42 (18)	<0.001
Previous	103 (13)	35 (11.6)	3 (1.2)	65 (27.9)	<0.001
Immunosuppressive regimen					
Cyclosporin monotherapy	85 (10.7)	3 (1)	68 (26.8)	14 (6)	<0.001
Cyclosporin and MMF	63 (8)	25 (8.3)	34 (13.4)	4 (1.7)	<0.001
Cyclosporin and everolimus	8 (1)	0	1 (0.4)	7 (3)	0.001
Cyclosporin and azathioprine	15 (1.9)	6 (2)	0	9 (3.9)	0.008
Tacrolimus monotherapy	79 (10)	17 (5.6)	43 (16.9)	19 (8.1)	<0.001
Tacrolimus and MMF	343 (43.5)	179 (59.3)	95 (37.4)	69 (29.6)	<0.001
Tacrolimus and everolimus	65 (8.2)	4 (1.3)	2 (0.8)	59 (25.3)	<0.001
Tacrolimus and azathioprine	5 (0.6)	3 (1)	0	2 (0.8)	NS
Everolimus monotherapy	42 (5.3)	2 (0.6)	4 (1.6)	36 (15.4)	<0.001
Everolimus and MMF	14 (1.8)	2 (0.7)	1 (0.4)	11 (4.7)	<0.001
Azathioprine monotherapy	14 (1.8)	14 (4.6)	0	0	<0.001
MMF monotherapy	39 (4.9)	33 (10.9)	6 (2.4)	0	<0.001
Induction therapy	8 (1.0)	0	8 (3.1)	0	<0.001
At least one rejection episodes	70 (8.9)	57 (18.9)	3 (1.2)	10 (4.3)	<0.001
Post-LT CMV infection	173 (21.9)	34 (11.3)	27 (10.6)	112 (48.1)	<0.001
Post-LT EBV infection	117 (14.8)	1 (0.3)	7 (2.8)	109 (46.8)	<0.001

Missing values: Age = 5, Immunosuppressive regimen = 17.

Abbreviations: IQR, interquartile ranges; LT, liver transplantation; HCV, hepatitis C virus; HBV, hepatitis B virus; MMF, mycophenolate mofetil; CMV, cytomegalovirus, EBV Epstein Barr Virus, PBC Primary Biliary Cholangitis, PSC Primary Sclerosing Cholangitis.

* In 142 cases, different pathologies in the same patient: HCV + alcohol = 102; HCV+HBV = 9; HCV+HBV + alcohol = 1; HBV + alcohol = 13; alcohol + autoimmune hepatitis = 6; alcohol + other = 10; alcohol + biliary cirrhosis = 1.

Within our cohort the median age was 55 years (range 18–76), and 600 (76%) patients were male. The most common indications for LT were HCV-related cirrhosis (39%) and alcohol-related cirrhosis (31%), while 35% of patients underwent LT because of HCC. History of alcohol use disorder and smoking was present in 35% and 22% of patients, respectively. The commonest immunosuppressive regimens were tacrolimus and mycophenolate mofetil (43%), tacrolimus monotherapy (10%) and cyclosporine monotherapy (10%). Post-LT Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) infection were reported for 22% and 15% of patients, respectively. Differences between the three centers are presented in table 1 and involved indications for liver transplantation, alcohol and smoking habits, and immunosuppressive regimens.

3.2. DNM incidence

Sixty-seven (5.5%) patients developed a non-cutaneous DNM (Table 2). The cumulative incidence of non-cutaneous DNM was 6.2% at 5-years, 11.6% at 10-years and 16.3% at 15-years (Fig. 1). Median follow-up was 81 months (IQR: 38–124). Post-Transplant Lymphoproliferative Disorders (PTLD) accounted for 9 cases, their cumulative incidence was observed to be 1.0% at 5-years, 1.6% at 10-years and 2.2% at 15-years. 3 of these patients developed EBV infection post-LT. Overall Solid Organ Tumors (SOT) accounted for the majority, representing 57 cases, with a cumulative incidence of 5.3% at 5-years, 10.3% at 10-years and 14.4% at 15-years. The most frequently observed classifications of SOT involved lung and head & neck tumors. Lung tumors accounted for 11 cases (7 non-small cell lung cancers, 3 small cell cancers, 1 neuroendocrine tumor) with




Fig. 1. Cumulative incidence of non-cutaneous DNM after LT.

a 5-years cumulative incidence of 1.0%; 45% of them occurred in patients with a history of smoking. Head & neck tumors, specifically squamous cell carcinomas, were diagnosed in 11 patients (8 larynx, 2 tongue, 1 pharynx), with a 5-years cumulative incidence of 1.3%; 50% of them occurred in patients with a history of alcohol and/or smoking. No statistical differences in the incidences of DNM were observed among the three centers.

Table 2
Cumulative incidence of De Novo Malignancy by site.

Site	N° case (on 789 LT)	Cumulative incidence 5 years after LT (n° at risk 465)	Cumulative incidence 10 years after LT (n° at risk 209)	Cumulative incidence 15 years after LT (n° at risk 48)
Lung	11	1.0%	2.5%	2.5%
Head and neck	11	1.3%	1.9%	1.9%
PTLD	9	1.0%	1.6%	2.2%
Breast	5	0.4%	0.7%	2.2%
Esophagus	4	0.4%	0.4%	1.9%
Prostate	4	0.2%	1.1%	1.1%
Pancreas	4	0.4%	0.7%	1.4%
Stomach	3	0.4%	0.7%	0.7%
Colon	3	0.2%	0.8%	0.8%
Kaposi	3	0.2%	0.5%	1.2%
Others*	10			
Solid organ tumor	57	5.3%	10.3%	14.4%
All non-cutaneous DNM	67	6.2%	11.6%	16.3%

PTLD Post-Transplant Lymphoproliferative Disorder; DNM De Novo Malignancy; LT Liver Transplantation.

* Other tumors include 3 bladder, 1 kidney, 1 cholangiocarcinoma, 1 bone, 1 neurinoma, 1 glioblastoma, 1 cervix uteri, 1 undifferentiated abdominal carcinoma.

Table 3
Cox regression analysis for the risk factors of the post-LT SOT.

Variables	Univariable analysis			Multivariable analysis		
	HR	95%CI	p	HR	95%CI	p
Male gender	1.15	0.62–2.13	0.66			
Age at LT	1.01	0.98–1.04	0.48			
HBV-related cirrhosis	1.23	0.65–2.31	0.52			
Alcohol-related cirrhosis	0.85	0.52–1.39	0.52			
Autoimmune hepatitis	0.61	0.08–4.47	0.63			
Colestatic diseases	1.05	0.25–4.34	0.94			
Acute Liver Failure	0.53	0.07–3.86	0.53			
Hepatocellular Carcinoma	0.59	0.35–1.01	0.06			
History of alcohol use disorder	0.91	0.54–1.54	0.73			
Smoking (any)	0.83	0.48–1.45	0.51			
Current	0.77	0.40–1.50	0.45			
Previous	0.96	0.41–2.25	0.92			
Cyclosporin monotherapy	0.79	0.42–1.49	0.48			
Cyclosporin and MMF	0.56	0.27–1.15	0.11			
Tacrolimus monotherapy	2.37	1.22–4.59	0.01			
Tacrolimus and MMF	0.68	0.39–1.17	0.16			
Tacrolimus and everolimus	2.69	0.64–11.3	0.17			
Everolimus monotherapy	1.0	1.0	0.5			
MMF monotherapy	1.35	0.33–5.56	0.68			
At least one rejection episode	1.60	0.49–5.20	0.43			
Post-LT CMV infection	2.22	1.22–4.06	0.01			
Post-LT EBV infection	1.39	0.72–2.69	0.33			
Pre-LT history of tumor	0.53	0.31–0.88	0.01			
Center						
A	1.00	–	–			
B	1.10	0.62–1.90	0.76			
C	2.26	1.15–4.42	0.02			

Abbreviations: HR, hazard ratio; CI, confidence intervals; LT, liver transplantation; HCV, hepatitis C virus; HBV, hepatitis B virus; MMF, mycophenolate mofetil; CMV, cytomegalovirus; EBV, Epstein Barr Virus.

Patients with non-cutaneous DNM were mainly male ($n = 52$, 78%) presenting at a median age at diagnosis of 59 years (IQR: 51–63). The median interval between LT and the diagnosis of the tumor was 47 months (IQR: 22–94). The interval between LT and DNM occurrence was different according to the type of tumor, with a median value of 33 months (IQR: 9–65) for PTLT, 43 months (IQR: 31–65) for head & neck tumors, and 59 months (IQR: 14–96) for lung tumors. Only one case of DNM was observed among 29 patients transplanted for acute liver failure and was a case of PTLT occurring 9 years after LT.

3.3. Risk factors

Risk factors associated with the development of SOT are reported in Table 3. In univariable analysis, tacrolimus monotherapy (HR 2.37; $p = 0.01$), post-LT CMV infection (HR 2.22; $p = 0.01$), pre-LT history of tumor (HR = 0.53; $p = 0.02$) were significantly

associated with SOT development. These isolated associations did not reach significance in multivariable analysis.

3.4. Outcomes

Table 4 shows SOT-related prognostic factors. As for the multivariable Cox regression analysis results, the presence of metastases at diagnosis (HR = 2.20; $P = 0.05$) was a border-line risk factor for mortality.

3.5. Subgroup analysis of LT patients according to transplant date

After splitting the population into two groups according to the date of transplantation (2000–2009 vs. 2010–2015), several differences were observed (Supplementary Table 1). In the more recent period, older patients were transplanted (median age 56 vs. 53 years; $p = 0.001$). Indications for LT remained similar, although

Table 4
Uni- and multivariate Cox regression analysis for mortality after SOT onset.

Variables	Univariable			Multivariable		
	HR	95%CI	P	HR	95%CI	P
Surgery	0.36	0.16–0.82	0.016			
Metastases at DNM diagnosis	2.89	1.35–6.20	0.006	2.20	0.98–4.93	0.05
Asymptomatic DNM at diagnosis	1.91	0.89–4.09	0.098	–	–	–
Age at DNM diagnosis	1.05	0.84–1.18	0.46	–	–	–
Male gender	0.88	0.38–2.04	0.76	–	–	–

Abbreviations: HR, hazard ratio; CI, confidence intervals; DNM, de-novo malignancy; LT, liver transplantation.

more patients received transplants for cryptogenic cirrhosis (5.1 vs. 2.1%; $p = 0.03$).

As for smoking history and alcohol use disorder, more cases were reported in recent years. However, such a result could have been influenced by more accurate data collection in the second period. Similarly, the greater number of post-LT CMV and EBV infections identified in this period could be related to such a phenomenon.

Immunosuppressive regimens significantly changed between the first and second era, with a progressive decline in the use of cyclosporine (cyclosporine monotherapy: 17.5 vs. 0.6%, $p < 0.0001$; cyclosporine + MMF: 12.5 vs. 1.3%, $p < 0.0001$), an increase in the use of tacrolimus (tacrolimus + MMF: 32.1 vs. 60.4; $p < 0.0001$), and introduction of everolimus (tacrolimus + everolimus: 2.5 vs. 16.8; $p < 0.0001$). Interestingly, the percentage of patients reporting a DNM within 5 years from LT was similar (4.4 vs. 6.0%; $p = 0.33$).

4. Discussion

Despite major advances in all aspects of pre- and post-operative management of patients with end-stage liver disease undergoing LT, malignancies are reported to be the most common cause of death in patients surviving at least one year [2,3,16]. For this reason, updated data concerning the incidence, risk factors and prognosis of DNM are important to target specific surveillance protocols in the post-transplant setting. Currently, surveillance protocols for cancer in patients that underwent LT were based on expert opinions, often derived from recommendations for the general population, and not always applied appropriately [6,17,18]. Furthermore, it may also happen that patients, underestimating the risks connected with the chronic immunosuppression, become less compliant with screening measures as time passes following transplantation.

In the present analysis, the incidence of DNM was not different among the three centers despite some differences in the immunosuppressive regimens. However, each center avoided high level of immunosuppressive drugs. We failed to demonstrate a role for immunosuppressive regimens or moderate target dosages in the development of DNM or PTLT.

The incidence of DNM after LT in our study was higher than that found in the general population [19]. In particular, the annual incidence per 100,000 of non-cutaneous malignancy in 55 year old males in the cancer registry of the same geographical area was about one third lower than that of our transplant population (7198 vs 10,866). The difference was even more pronounced when comparing the most frequent types of cancer in our cohort: lung (1194 vs 250), hematologic malignancy (646 vs 220) and head & neck tumors (488 vs 190).

Our cumulative incidences of non-cutaneous DNM (6.2% at 5-years and 11.6% at 10-years) are comparable with older publications [4,15,20–24]. Specifically, a German single-centre study analysing the period 1988–2006 reported cumulative incidence of 7% at 5-years and 12.9% at 10-years [4]. A Dutch single-centre study analysing the period 1986–2007 reported a cumulative incidence of 5.4% at 5-years and 10.8% at 10-years [15]. Similar data (cumula-

tive incidence rates of 4% at 5-years and 9% at 10-years) came also from Nordic LT Registry analyzing the period 1982–2013 [20].

Notably however, the incidences of each classification of DNM in our series were different than reported elsewhere. Firstly, we observed lower cumulative incidences for PTLT compared to those reported in the literature. We report incidences of 1.0% at 5-years and 1.6% at 10-years whereas rates of 1.6% at 5-years and 2.3% at 10-years were seen in the German study [4], 2.8% at 5-years and 6.4% at 10-years in the Dutch study [15] and even higher in older series [21,24,25]. However, the study is underpowered to make definitive assumptions about PTLT as a separate entity. The reasons for these differences surpass the purposes of our study, but current practice of routine monitoring of EBV-DNA viremia and pre-emptive reduction of immunosuppression in patients at high-risk of EBV-DNA viremia may play a role [26]. Unfortunately, a screening protocol for these tumors presently does not exist.

In our cohort, the most common SOT were lung and head & neck tumors, which are traditionally linked to smoking and alcohol habit [27]. An Italian multicenter case-control study confirmed a significant impact on mortality for both cancers; HR = 37.13 for lung cancer and 4.65 for head & neck cancers [28]. In this multi-centre series the number of lung and head-neck tumors was fortunately low. Nevertheless, regular counseling on smoking cessation should be mandatory for all LT patients both in the short and in the long term and a cessation should start at the time of evaluation for LT listing. Herrero et al. demonstrated that smoking withdrawal after liver transplantation may have a protective effect against the development of cancer [29]. Currently, surveillance protocols for these tumor subtypes in the setting of LT do not exist and risk stratification of LT patients seems the most promising approach to implement effective and applicable screening protocols. The screening proposal of Burra et al. includes yearly thoracic CT scanning in active smokers, and ears, nose and throat examination in patients transplanted for alcoholic liver disease, especially with contemporaneous smoking habit [17]. Future research should prospectively validate these types of surveillance program.

This study has some limitations. Firstly, the study is retrospective and examines a 15-year period. These shortcomings limited our possibility to systematically collect the immunosuppressive blood levels to assess whether adverse effects were dose-dependent. Thus, a safer immunosuppressive threshold could not be determined. Moreover, the switch from dual to mono-therapy during this period was not investigated due to the difficulties in collecting regime changes during a 15-year period.

Second, both smoking and alcohol use disorder were analyzed using less granular, often dichotomous, variables, due to the difficulty in collecting daily usage and duration of abuse for all study participants. We also could not collect smoking and alcohol status before and after transplant separately. Lastly, some interesting variables like diabetes mellitus and metabolic syndrome before or after LT, and the episodes of acute rejection were not considered in the analysis, due to missing data in the database. Despite these limitations the differences in the immunosuppressive regimens among

centers constitute a strength and allow a potential stratification of results.

In conclusion, our study demonstrates that lung and head & neck tumors are the most frequent SOT after LT. Our data support the development of surveillance programs for these tumors as a priority. Immunosuppressive regimes do not appear to be associated with different incidences of DNM.

Financial support

None.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

We thank Dr. Christopher Oddy (Epsom & St Helier University Hospitals NHS Trust, United Kingdom) for proof-reading the text.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.aohep.2021.100309>.

References

- [1] <http://optn.transplant.hrsa.gov>. [Accessed 20 July 2020].
- [2] Aberg F, Gissler M, Karlsson TH, Ericzon BG, Foss A, Rasmussen A, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. *Hepatology* 2015;61:668–77.
- [3] Daniel KE, Eickhoff J, Lucey MR. Why do patients die after a liver transplantation? *Clin Transplant* 2017;31.
- [4] Rademacher S, Seehofer D, Eurich D, Schoening W, Neuhaus R, Re Oellinger, et al. 28-year incidence of de novo malignancies after liver transplantation: a single-center analysis of risk factors and mortality in 1616 patients. *Liver Transplant* 2017;23:1404–14.
- [5] Zhou J, Hu Z, Zhang Q, Li Zhiwei, Xiang Jie, Yan Sheng, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the Scientific Registry of Transplant Recipients Database. *PLoS One* 2016;11:e0155179.
- [6] Burra P, Rodríguez-Castro KI. Neoplastic disease after liver transplantation: focus on de novo neoplasms. *World J Gastroenterol* 2015;21:8753–68.
- [7] Martinez OM, De Gruil FR. Molecular and immunologic mechanisms of Cancer pathogenesis in solid organ transplant recipients. *Am J Transplant* 2008;8:2205–11.
- [8] Carencio C, Faure S, Herrero A, Assenat E, Duny Y, Ge Danan, et al. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors. *Liver Int* 2015;35:1748–55.
- [9] Sherston SN, Carroll RP, Harden PN, Wood KJ. Predictors of cancer risk in the long-term solid-organ transplant recipient. *Transplantation* 2014;97:605–11.
- [10] Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. *Transpl Int* 2014;27(10):1039–49.
- [11] Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: randomized, multicenter, open-label phase 3 trial. *Transplantation* 2016;100(January (1)):116–25.
- [12] Dumortier J, Maucourt-Boulch D, Poinson D, Thimonier E, Chambon-Augoyard C, Ducroux E, et al. Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease. *Clin Res Hepatol Gastroenterol* 2018;42(5):427–35.
- [13] Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. *J Hepatol* 2018;69(4):810–7.
- [14] Sanna C, Rosso C, Marietti M, Bugianesi E. Nonalcoholic fatty liver disease and extra-hepatic cancers. *Int J Mol Sci* 2016;17.
- [15] Tjon AS, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. *Liver Transpl* 2010;16(July (7)):837–46.
- [16] Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. *Gastroenterology* 2009;137:2010–7.
- [17] Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: de novo neoplasms after liver transplantation. *Curr Opin Organ Transplant* 2018;23(2):187–95.
- [18] Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. *Liver Transpl* 2012;18(11):1277–89.
- [19] Cancer Incidence in Five Continents Volume IX, International Agency for Research on Cancer. www.iarc.fr/.
- [20] Nordin A, Aberg F, Pukkala E, Pedersen CR, Storm HH, Rasmussen A, et al. Decreasing incidence of cancer after liver transplantation—a Nordic population-based study over three decades. *Am J Transplant* 2018;18(April (4)):952–63.
- [21] Ettorre GM, Piselli P, Galatioto L, Rendina M, Nudo F, Sforza D, et al. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990–2008. *Transplant Proc* 2013;45(September (7)):2729–32.
- [22] Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. *J Hepatol* 2001;34:84–91.
- [23] Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single Center. *Ann Surg* 2000;232:490–500.
- [24] Baccarani U, Adani GL, Serraino D, Lorenzin D, Gambato M, Buda A, et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. *Transplant Proc* 2009;41:1303–5.
- [25] Avolio AW, Agnes S, Barbarino R, Magalini SC, Frongillo F, Pagano L, et al. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series. *Transplant Proc* 2007;39(6):1956–60.
- [26] San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Crosssectional Survey. *Clin Microbiol Infect* 2015;21(6), 604.e1–9.
- [27] Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Møller M, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. *Hepatology* 1998;28(4):921–5.
- [28] Taborelli M, Piselli P, Ettorre GM, Baccarani U, Burra P, Lauro A, et al. Italian Transplant and Cancer cohort Study. Survival after the diagnosis of de novo malignancy in liver transplant recipients. *Int J Cancer* 2019;144(2):232–9.
- [29] Herrero JL, Pardo F, D'Avola D, Alegre F, Rotellar F, Iñarrairaegui M, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. *Liver Transpl* 2011;17(April (4)):402–8.